Company news
Entrada Therapeutics, Inc. news in 2024
Entrada Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
November 4, 2024
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
October 8, 2024
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
September 23, 2024
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
September 5, 2024
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 12, 2024
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 23, 2024
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 23, 2024
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 2, 2024
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15, 2024
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 6, 2024
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 2, 2024